SIK1-LNC represses the proliferative, migrative, and invasive abilities of lung cancer cells.

Liu Yang, Nianlin Xie, Jingyu Huang, Hu Huang, Shaogan Xu, Zhigang Wang, Jun Cai
Author Information
  1. Liu Yang: Department of Cancer Biotherapy Center, Hubei Cancer Hospital, Wuhan 430079, Hubei, People's Republic of China.
  2. Nianlin Xie: Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military Medical University, Xi'an 710038, Shaanxi, People's Republic of China.
  3. Jingyu Huang: Department of Thoracic and Cardiovascular Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei, People's Republic of China.
  4. Hu Huang: Department of Oncology, The 161th Hospital of PLA, Wuhan, Hubei 430010, People's Republic of China, wangzhigang16824@163.com.
  5. Shaogan Xu: Department of Thoracic Surgery, The 161th Hospital of PLA, Wuhan, Hubei 430010, People's Republic of China.
  6. Zhigang Wang: Department of Oncology, The 161th Hospital of PLA, Wuhan, Hubei 430010, People's Republic of China, wangzhigang16824@163.com.
  7. Jun Cai: Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou 434000, Hubei, People's Republic of China, caijun0540@163.com.

Abstract

BACKGROUND: Discussions regarding the correlations between long non-coding RNAs (lncRNAs) and cancers have dominated research in recent years. SIK1-LNC, a type of lncRNA and adjacent to salt-inducible kinases 1 (SIK1), has been found aberrantly expressed in lung cancer. However, its functional role in lung cancer remains largely unknown.
PURPOSE: In this study, we aimed to explore the association between SIK1-LNC expression and SIK1 in lung cancer cells and further identify the impact of SIK1-LNC on the proliferation, migration invasion of lung cancer cells.
PATIENTS AND METHODS: Of the 30 patients with non-small-cell lung carcinoma from Zhongnan Hospital of Wuhan University, RT-qPCR was performed to detect SIK1 and SIK1-LNC expressions in patients' samples. Overexpression and knockdown experiments were conducted to analyze the SIK1 and SIK1-LNC expressions in lung cancer cell lines. CCK-8, Brdu, scratch wound-healing, and Transwell assays were respectively employed to evaluate the proliferative, migrative, and invasive abilities of lung cancer cells.
RESULTS: Both SIK1-LNC and SIK1 expression levels were evidently downregulated in 30 lung cancer tissues. SIK1-LNC expression was bound up with clinicopathologic features, including lymph node metastasis and distant metastasis. SIK1 expression showed a positive tendency with SIK1-LNC expression in lung cancer cells. SIK1-LNC exerted a significant repression on cell proliferatiive, miogrative and invasive abilities of lung cancer cells.
CONCLUSION: Our findings suggested that SIK1-LNC may act as a novel biomarker and therapeutic target for lung cancer.

Keywords

References

  1. Mol Med Rep. 2016 May;13(5):4481-6 [PMID: 27035680]
  2. Nucleic Acids Res. 2011 Sep 1;39(16):7179-93 [PMID: 21596787]
  3. Anticancer Res. 2013 Aug;33(8):3185-93 [PMID: 23898077]
  4. J Integr Med. 2017 Jul;15(4):265-269 [PMID: 28659230]
  5. J Integr Med. 2017 Jul;15(4):282-287 [PMID: 28659232]
  6. J Integr Med. 2014 May;12(3):175-81 [PMID: 24861837]
  7. Eur J Cancer. 2013 Sep;49(13):2949-59 [PMID: 23726266]
  8. BMC Cancer. 2014 Sep 23;14:697 [PMID: 25245473]
  9. J Integr Med. 2017 May;15(3):242-251 [PMID: 28494854]
  10. Oncol Rep. 2018 Mar;39(3):1072-1080 [PMID: 29328452]
  11. Cancer J. 2015 Sep-Oct;21(5):366-70 [PMID: 26389760]
  12. Chin J Cancer. 2016 Jun 07;35:50 [PMID: 27266881]
  13. Biochemistry. 2015 Nov 24;54(46):6917-30 [PMID: 26567857]
  14. Sci Signal. 2009 Jul 21;2(80):ra35 [PMID: 19622832]
  15. Int J Mol Sci. 2014 Oct 20;15(10):18985-99 [PMID: 25334066]
  16. PLoS One. 2014 Jan 23;9(1):e86295 [PMID: 24466011]
  17. Funct Integr Genomics. 2017 May;17(2-3):135-143 [PMID: 27681237]
  18. Mol Cancer. 2017 Aug 17;16(1):138 [PMID: 28818073]
  19. Int J Cancer. 2015 Sep 1;137(5):1128-35 [PMID: 25694351]
  20. BioData Min. 2015 Dec 22;8:44 [PMID: 26697116]
  21. Oncogene. 2012 Oct 25;31(43):4577-87 [PMID: 22266873]
  22. Mol Cancer. 2018 Jan 12;17(1):6 [PMID: 29329543]
  23. Oncotarget. 2015 Feb 28;6(6):4505-15 [PMID: 25714016]
  24. PLoS One. 2015 May 01;10(5):e0122143 [PMID: 25933431]
  25. Cancer Lett. 2018 May 1;421:121-126 [PMID: 29331418]
  26. Oncol Res. 2017 Mar 13;25(3):373-380 [PMID: 27662619]
  27. Oncol Res. 2016;24(3):161-70 [PMID: 27458097]
  28. Oncol Rep. 2016 Nov;36(5):2673-2680 [PMID: 27666964]
  29. PLoS One. 2014 Nov 10;9(11):e112485 [PMID: 25384047]
  30. Nat Commun. 2014 Nov 21;5:5383 [PMID: 25415230]
  31. Cancer Res. 2011 Jan 1;71(1):3-7 [PMID: 21199792]
  32. Tumour Biol. 2016 Jun;37(6):8349-58 [PMID: 26729200]
  33. Hum Mol Genet. 2010 Oct 15;19(R2):R152-61 [PMID: 20729297]
  34. Biomed Pharmacother. 2016 Oct;83:8-13 [PMID: 27470544]

Word Cloud

Created with Highcharts 10.0.0lungSIK1-LNCcancerSIK1cellsexpressioninvasiveabilitiesmetastasisproliferationinvasion30expressionscellproliferativemigrativeBACKGROUND:Discussionsregardingcorrelationslongnon-codingRNAslncRNAscancersdominatedresearchrecentyearstypelncRNAadjacentsalt-induciblekinases1foundaberrantlyexpressedHoweverfunctionalroleremainslargelyunknownPURPOSE:studyaimedexploreassociationidentifyimpactmigrationPATIENTSANDMETHODS:patientsnon-small-cellcarcinomaZhongnanHospitalWuhanUniversityRT-qPCRperformeddetectpatients'samplesOverexpressionknockdownexperimentsconductedanalyzelinesCCK-8Brduscratchwound-healingTranswellassaysrespectivelyemployedevaluateRESULTS:levelsevidentlydownregulatedtissuesboundclinicopathologicfeaturesincludinglymphnodedistantshowedpositivetendencyexertedsignificantrepressionproliferatiivemiogrativeCONCLUSION:findingssuggestedmayactnovelbiomarkertherapeutictargetrepresses

Similar Articles

Cited By